Low-Dose CT for Lung Cancer Screening
(MAS-EXPAND Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Lung cancer screening with low-dose chest computed tomography (CT) is currently recommended for high-risk individuals who are 50 to 80 years old, have smoked cigarettes for at least 20 pack-years, and currently smoke or quit smoking within the past 15 years. In a prospective cohort at Nashville, Denver, Louisville, Chicago, Kansas City, Salisbury and Seattle Veteran Affairs medical centers, the investigators will evaluate the detection of lung cancer using an expanded screening eligibility criteria based on Veterans' personal and service-related exposures compared to standard of care criteria. Screening a larger population will increase the number of lung nodules needing clinical management and these nodules may or may not be cancer. In a population of Veterans with positive screenings at Nashville, the investigators will also validate a combination biomarker-based approach to manage screen-detected lung nodules to reduce time to lung cancer diagnosis and use of invasive procedures. This study will also convene a Veteran Community Advisory Board and interview Veterans to better understand their thoughts about lung cancer screening and preferences for outreach and engagement.
Who Is on the Research Team?
Jennifer A Lewis, MD MS MPH
Principal Investigator
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
Are You a Good Fit for This Trial?
This trial is for Veterans who may be at risk for lung cancer due to factors like smoking, toxic exposures (such as asbestos or Agent Orange), family history of lung cancer, or certain lung diseases. Participants are mainly adults being seen at select VA medical centers.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Low-dose computed tomography
Trial Overview
The study is testing whether expanding the criteria for low-dose chest CT scans helps find more cases of lung cancer in Veterans compared to current guidelines. It also looks at using blood tests (biomarkers) to better manage suspicious spots found on scans.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All study participants enrolled receive annual screening for lung cancer with low-dose computed tomography (LDCT)
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania
Vanderbilt-Ingram Cancer Center
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.